Visium SA, the AI and data partner for enterprises in highly regulated industries, has announced the successful close of its first institutional funding round.
The round was co-led by Columbus Venture Partners and Concentric, with participation from a curated syndicate of unicorn founders.
The amount raised is not being disclosed.
With this funding, Visium is accelerating its expansion across Europe and the United States, scaling its team and product capabilities to bring its approach to a broader set of global enterprises.
Visium has been recognised among the Financial Times’ Top 100 Fastest Growing Companies in Europe.
Alen Arslanagic, CEO and Founder, Visium SA, said: “This round is not about capital alone. It is about aligning ourselves with investors and operators whose DNA we admire.
“Columbus brings unmatched experience scaling life sciences ventures, Concentric brings an activist partnership mindset that mirrors how we work with our own clients, and the operators joining us have built some of the most important AI and technology companies of the past decade.
“We could not be more ready for the next chapter.”
Visium transforms core business functions through an AI-native approach, rethinking workflows from first principles rather than incrementally improving existing processes.
This is made possible by an integrated operating model that combines a first-class strategy team, forward-deployed AI engineers and data scientists, and domain experts with deep scientific and technical backgrounds in regulated industries, enabling the company to design and deploy systems that work in real-world environments.
This approach is reinforced by a dual structure that combines consulting with a growing portfolio of products.
Consulting keeps Visium close to real operational challenges, while its products turn these insights into scalable solutions that enable scalable impact, as opposed to one-off implementations.
Columbus Venture Partners is a Spanish venture capital firm specialised in biotechnology and life sciences.
With over €800 million in assets under management, the firm operates a differentiated investment model and has built a strong track record in developing industrial platforms for advanced therapies.
Columbus Venture Partners plays an active role in the creation and growth of more than 80 per cent of its portfolio companies.
Damià Tormo, General Partner, Columbus Venture Partners, said: “Our investment in Visium is driven by the clear thesis that generative AI is redefining operational processes across the pharmaceutical and biotechnology industries.
“Its ability to design, automate, and optimise complex workflows in an agile manner enables pharma companies, CROs, and R&D teams to significantly reduce timelines and the operational burden associated with drug development.”
Concentric, the London-based “activist venture” fund co-founded by Kjartan Rist and Denis Shafranik, invests in software-driven businesses transforming traditional sectors and is known for its hands-on partnership model with founders.
Denis Shafranik, Co-founder and Partner, Concentric, said: “What Visium is doing — embedding world-class engineers deep inside complex enterprises to deliver AI that actually works — is a blueprint for how traditional industries will be transformed.
“That mission sits at the heart of Concentric’s activist approach, and we’re proud to back them for the next chapter.”
Alongside the financing, Visium is announcing four strategic appointments to its Board of Directors.
- Sam Bourton, Co-founder of QuantumBlack, former McKinsey AI Partner
- Javier Fernández, Operating Partner, Columbus Venture Partners; former CEO of Vitro S.A.
- Denis Shafranik, Co-founder and Partner, Concentric
- Urban Lankes, Chairman of biGENIUS and Coople Switzerland.
To deepen its scientific and commercial expertise, Visium is also announcing three new appointments to its Advisory Board:
- Jayanth Sridhar, CEO of AveThera GmbH
- Dr. Christiane Hamacher, Former pharma and biotech executive and CEO
- Peter Sarlin, Founder of Silo AI (acquired by AMD); now Founder and Chairman of PostScriptum, QuTwo, NestAI
Founded in 2018 and headquartered in Lausanne, Switzerland, Visium has grown from a fully bootstrapped company to 100 AI experts across Europe, delivering more than 250 AI and data solutions for global leaders in life sciences, specialty chemicals, and other highly regulated industries.
Its clients include Roche, Novartis, and several top 20 pharmaceutical companies, as well as specialty chemicals leaders including dsm-firmenich, where Visium collaborated on a frontier AI innovation recognised at the Swiss Digital Economy Awards 2021.
Learn more about Visium at visium.com
